Guerbet : 2025 revenue.

Core Viewpoint - Guerbet reported a 6.5% decline in sales for the full year 2025, totaling €786.4 million, with a more moderate decline of 3.8% at constant exchange rates (CER) [3][10]. Financial Performance - The decline in sales was primarily attributed to a 5.4% drop in the first half of the year, followed by a 2.6% increase in Q3, and a 5.6% decline in Q4, influenced by issues at the Raleigh industrial site in the U.S. [4][10]. - Revenue breakdown for Q4 2025 showed a total of €200.0 million, down 9.4% compared to Q4 2024, with a decline of 5.6% at CER [5][11]. Geographical Breakdown - In EMEA, full-year sales were €343.7 million, down 2.5% at CER, with a notable growth of 7.6% excluding France [7]. - The Americas reported revenue of €233.0 million, a decrease of 3.8% at CER, with a significant contraction of 8.6% in Q4 due to production delays at the Raleigh site [8]. - In Asia, sales totaled €207.9 million, down 4.8% at CER, impacted by the loss of a customer in Vietnam [9]. Segment Performance - Diagnostic Imaging revenue for the year was €678.2 million, a decrease of 5.3% at CER, with a 9.1% decline in Q4 [11]. - Interventional Imaging saw revenue increase to €106.3 million, up 9.7% at CER, driven by strong demand for Lipiodol in vascular embolization [12]. Future Outlook - The company confirmed its forecast for a restated EBITDA margin between 10.5% and 12% for 2025 and revised its Free cash flow target to be positive [13]. - The ongoing situation at the Raleigh site is expected to continue affecting revenue, profitability, and cash generation in 2026 [15][16].